Last reviewed · How we verify
levels of CNI in whole blood
levels of CNI in whole blood is a Biologic drug developed by Assistance Publique Hopitaux De Marseille. It is currently in Phase 1 development.
At a glance
| Generic name | levels of CNI in whole blood |
|---|---|
| Sponsor | Assistance Publique Hopitaux De Marseille |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Oedema peripheral
- Diarrhoea
- Hypertension
- Constipation
- Anaemia
- Urinary tract infection
- Nausea
- Hypophosphataemia
- Hyperkalaemia
- Hypokalaemia
- Blood creatinine increased
- Headache
Key clinical trials
- Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation (PHASE2)
- Screening for Subclinical Antibody Mediated Rejection and Efficacy of Belatacept in the Context of de Novo Donor Specific Antibody After Kidney Transplantation (BELA-M-R) (PHASE2, PHASE3)
- Treg Therapy in Subclinical Inflammation in Kidney Transplantation (PHASE1, PHASE2)
- Study to Compare the Outcome of Receiving Continued Immunosuppression Versus Stopping Immunosuppression at 6 Months to Safely Prevent Human Leukocyte Antigen (HLA) Sensitization in Patients With Late Renal Graft Failure (PHASE4)
- Selective CD28 Blockade in Renal Transplant Recipients (PHASE2)
- Optimization of NULOJIX® Usage Towards Minimizing CNI Exposure in Simultaneous Pancreas and Kidney Transplantation (PHASE2)
- Open-Label Phase 2 Trial of a Steroid-Free, CNI-Free, Belatacept-Based Immunosuppressive Regimen (PHASE2)
- Nordic Everolimus (Certican) Trial in Heart and Lung Transplantation (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- levels of CNI in whole blood CI brief — competitive landscape report
- levels of CNI in whole blood updates RSS · CI watch RSS
- Assistance Publique Hopitaux De Marseille portfolio CI
Frequently asked questions about levels of CNI in whole blood
What is levels of CNI in whole blood?
levels of CNI in whole blood is a Biologic drug developed by Assistance Publique Hopitaux De Marseille.
Who makes levels of CNI in whole blood?
levels of CNI in whole blood is developed by Assistance Publique Hopitaux De Marseille (see full Assistance Publique Hopitaux De Marseille pipeline at /company/assistance-publique-hopitaux-de-marseille).
What development phase is levels of CNI in whole blood in?
levels of CNI in whole blood is in Phase 1.
What are the side effects of levels of CNI in whole blood?
Common side effects of levels of CNI in whole blood include Oedema peripheral, Diarrhoea, Hypertension, Constipation, Anaemia, Urinary tract infection.